Radiolabeling of the rat P2X4 purinoceptor: evidence for allosteric interactions of purinoceptor antagonists and monovalent cations with P2X purinoceptors.

The rat recombinant P2X4 purinoceptor was expressed in CHO-K1 cells, and binding studies were performed using the radioligand [35S]adenosine-5'-O-(3-thio)triphosphate ([35S]ATPgammaS). In 50 mM Tris/1 mM EDTA assay buffer, pH 7.4 at 4 degrees, [35S]ATPgammaS bound with high affinity to the P2X4 purinoceptor (KD = 0.13 nM, Bmax = 151 pmol/mg of protein). The purinoceptor agonists ATP and 2-methylthioadenosine triphosphate possessed nanomolar affinity for the P2X4 purinoceptor, whereas the antagonist suramin possessed much lower affinity (IC50 = 0.5 mM). Cibacron blue was more potent than suramin but produced a biphasic competition curve, whereas d-tubocurarine potentiated binding at concentrations in excess of 10 microM. The complex effects of cibacron blue and d-tubocurarine seemed to be due to an allosteric interaction with the P2X4 purinoceptor because these compounds affected radioligand dissociation, measured after isotopic dilution with unlabeled ATPgammaS. Cibacron blue (1-100 microM) and d-tubocurarine (0.1-1 mM) produced rapid (10 sec to 5 min) decreases or increases, respectively, in the level of [35S]ATPgammaS binding measured immediately after initiation of the dissociation reaction. However, the subsequent rates of radioligand dissociation were not markedly different from those measured in their absence. Monovalent cations produced similar affects on the P2X4 purinoceptor and, like d-tubocurarine, increased [35S]ATPgammaS binding. The actions of d-tubocurarine and sodium were not additive. The findings from this study indicate that [35S]ATPgammaS can be used to label the P2X4 purinoceptor and suggest that this binding can be enhanced by monovalent cations and d-tubocurarine and may be subject to negative allosteric modulation to varying degrees by different purinoceptor antagonists.

[1]  K. Lundstrom,et al.  The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]‐αβmeATP, [35S]‐ATPγS or 33[P]‐ATP , 1996 .

[2]  R. North,et al.  Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons , 1995, Nature.

[3]  R. North,et al.  A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP , 1994, Nature.

[4]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[5]  R. North,et al.  An antagonist‐insensitive P2X receptor expressed in epithelia and brain. , 1996, The EMBO journal.

[6]  N. Adami,et al.  High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system. , 1994, European journal of biochemistry.

[7]  R. Marshall,et al.  Suramin: a selective inhibitor of purinergic neurotransmission in the rat isolated vas deferens. , 1992, European journal of pharmacology.

[8]  P. Liljeström,et al.  A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon , 1991, Bio/Technology.

[9]  D. Julius,et al.  New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor , 1994, Nature.

[10]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[11]  S. Lazareno,et al.  Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.

[12]  R. North,et al.  Cloning OF P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  S. Palea,et al.  Evidence for the presence of both pre‐ and postjunctional P2‐purinoceptor subtypes in human isolated urinary bladder , 1995, British journal of pharmacology.

[14]  Geoffrey Burnstock,et al.  A P2X purinoceptor cDNA conferring a novel pharmacological profile , 1995, FEBS letters.

[15]  G. Burnstock,et al.  A P2X purinoceptor expressed by a subset of sensory neurons , 1995, Nature.

[16]  E. Kawashima,et al.  The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7) , 1996, Science.

[17]  A. Michel,et al.  High affinity P2x‐purinoceptor binding sites for [35S]‐adenosine 5′‐0‐[3‐thiotriphosphate] in rat vas deferens membranes , 1996, British journal of pharmacology.

[18]  C. Barajas-López,et al.  Suramin increases the efficacy of ATP to activate an inward current in myenteric neurons from guinea-pig ileum. , 1993, European journal of pharmacology.

[19]  S. Valera,et al.  A comparison of the binding characteristics of recombinant P2×1 and P2×2 purinoceptors , 1996, British journal of pharmacology.

[20]  P. Humphrey,et al.  The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by α,β‐methylene adenosine 5′‐triphosphate , 1994 .